Vnitr Lek 2019, 65(5):377-378 | DOI: 10.36290/vnl.2019.067

Use of idarucizumab in clinical practice: a case report

Libuše Husová
Centrum kardiovaskulární a transplantační chirurgie, Brno

Budd-Chiari syndrome is a serious condition which in chronic course leads to the development of liver cirrhosis. Anti-coagulant treatment of this syndrome is fully indicated and in the treatment can be used dabigatran. Advanced cirrhosis of the liver due to this disease can be an indication for a liver transplant. In this case, it is a great advantage the existence of an antidote to dabigatran (idarucizumab) in order to adjust the coagulation ratios and prevent bleeding disorders. Referred to a case report describes the first experience with idarucizumab in context with liver transplant in a patient with Budd-Chiari syndrome

Keywords: antidote; bleeding; dabigatran; direct oral anticoagulants (DOAC); idarucizumab; liver transplant

Received: August 28, 2018; Accepted: November 7, 2018; Published: May 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husová L. Use of idarucizumab in clinical practice: a case report. Vnitr Lek. 2019;65(5):377-378. doi: 10.36290/vnl.2019.067.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Šembera Š, Hůlek P. Onemocnění jaterních cév. In: Hůlek P, Urbánek P et al. Hepatologie. 3. vydání. Grada: Praha 2018. ISBN 437-451.978-80-271-0394-2.
    2. Warfarin. Souhrn údajů o přípravku. Informace z WWW: http://www.sukl.cz.
    3. Kvasnička J, Penka M, Kvasnička T et al. Doporučení České společnosti pro trombózu a hemostázu J. E. Purkyně pro bezpečnou léčbu novými antikoagulancii (NOAC) - dabigatran etexilátem, apixabanem a rivaroxabanem. Vnitř Lék 2015; 61(6): 537-546. Go to PubMed...
    4. Pradaxa. Souhrn údajů o přípravku. Informace z WWW: http://www.sukl.cz.
    5. Pollack CV, Reilly PA, Eikelboom J et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373(6): 511-520. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1502000>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.